Wedbush reaffirmed their outperform rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a research report sent to investors on Wednesday morning, RTT News reports. Wedbush currently has a $77.00 price target on the stock, up from their prior price target of $75.00. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.56) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.92) EPS, FY2026 earnings at $0.49 EPS and FY2027 earnings at $3.56 EPS.
Separately, HC Wainwright restated a buy rating and set a $76.00 price objective on shares of SpringWorks Therapeutics in a research report on Wednesday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of Buy and a consensus price target of $69.50.
Check Out Our Latest Report on SpringWorks Therapeutics
SpringWorks Therapeutics Stock Performance
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.58. The firm had revenue of $59.73 million during the quarter, compared to the consensus estimate of $34.42 million. SpringWorks Therapeutics’s quarterly revenue was up 59732900.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.25) earnings per share. On average, research analysts predict that SpringWorks Therapeutics will post -3.34 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. First Horizon Advisors Inc. grew its position in SpringWorks Therapeutics by 47.9% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock worth $45,000 after acquiring an additional 383 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth about $74,000. Strs Ohio bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth about $102,000. Allspring Global Investments Holdings LLC acquired a new position in shares of SpringWorks Therapeutics in the second quarter valued at approximately $123,000. Finally, Quarry LP raised its holdings in SpringWorks Therapeutics by 56.3% in the 2nd quarter. Quarry LP now owns 5,000 shares of the company’s stock valued at $188,000 after buying an additional 1,800 shares during the last quarter.
SpringWorks Therapeutics Company Profile
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Featured Articles
- Five stocks we like better than SpringWorks Therapeutics
- 5 discounted opportunities for dividend growth investors
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- How to Invest in the FAANG Stocks
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.